Glenmark Pharmaceuticals ltd — Capital/Financing Update 2019

Jan 10, 2019

==> picture [16 x 10] intentionally omitted <==

==> picture [17 x 11] intentionally omitted <==

==> picture [141 x 42] intentionally omitted <==

January 10, 2019

To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001.

To, The Manager – Listing, The National Stock Exchange of India Ltd., Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Glenmark Pharmaceuticals enters into an Exclusive Licensing Agreement with Yuhan Corporation for commercializing Investigational Seasonal Allergic Rhinitis Nasal Spray Ryaltris in South Korea

Dear Sir,

With reference to the subject mentioned above, kindly find attached media release which is self explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Limited

HARISH Digitally signed by HARISH VINAYAK KUBER VINAYAK KUBER Date: 2019.01.10 09:03:15 +05'30'

Harish Kuber Company Secretary & Compliance Officer

Encl: as above

Glenmark Pharmaceuticals Ltd. Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

==> picture [561 x 80] intentionally omitted <==

Press Release

For Immediate Release

Glenmark Pharmaceuticals enters into an Exclusive Licensing Agreement with Yuhan Corporation for commercializing Investigational Seasonal Allergic Rhinitis Nasal Spray Ryaltris in South Korea

• This agreement with Yuhan marks Glenmark’s second regional licensing deal for Ryaltris

• As per the terms of the collaboration, Glenmark will be responsible for manufacturing and supply of the product, while Yuhan will be responsible for regulatory filing and commercialization of Ryaltris in South Korea

• Glenmark will receive an upfront payment, regulatory and commercial milestone payments and royalties from Yuhan for Ryaltris

Mumbai, India, January 10, 2019: Glenmark Pharmaceuticals Ltd. (Glenmark), a research‐led global integrated pharmaceutical company, today announced that its Suisse subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Yuhan Corporation for commercializing its novel nasal spray Ryaltris in South Korea.

The agreement with Yuhan is Glenmark’s second regional licensing deal for Ryaltris. In July 2018, Glenmark entered into an exclusive licensing agreement with Seqirus Pty. Ltd. to commercialize Ryaltris in Australia and New Zealand.

Ryaltris [olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)], developed by Glenmark, is a novel, investigational, fixed‐dose combination nasal spray of an anti‐histamine and a steroid, indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age .

Under the terms of the agreement, Glenmark will be responsible for manufacturing and supply of the product, while Yuhan will be responsible for regulatory filing and commercialization of Ryaltris in South Korea. Glenmark will receive an upfront payment, regulatory and commercial milestone payments as well as royalties from Yuhan.

“This partnership with Yuhan is in line with our vision to make Ryaltris the first global brand of Glenmark by launching it in several key markets. We are happy to collaborate with Yuhan as it is a strong and reputed player in South Korea and is aligned with Glenmark’s objective to provide quality novel products to fulfill unmet needs of patients,” said Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals.

==> picture [561 x 28] intentionally omitted <==

1

==> picture [561 x 80] intentionally omitted <==

In May 2018, Glenmark filed a New Drug Application (NDA) for Ryaltris with the US Food and Drug Administration (US FDA), which is currently under review with the regulator.

Glenmark plans to commercialize Ryaltris in various markets globally. The company will continue to explore commercial partnerships for Ryaltris in markets where it doesn’t have direct presence.

‐‐End‐‐

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd. (GPL) is a research‐driven, global, integrated pharmaceutical organization. It is ranked among the top 75 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2018). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory.

The company has a significant presence in the branded generics markets across emerging economies including India. Glenmark has 16 manufacturing facilities across five countries and has six R&D centers. The Generics business of Glenmark services the requirements of the US and Western European markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.

About Yuhan Corporation

Yuhan Corporation is a South Korea‐based healthcare company founded in 1926. It is positioned as the top pharmaceutical company in the Korean industry. The core business consists of primary & specialty care, dietary supplements, household & animal care, and contract manufacturing of active pharmaceutical ingredients.

For further information, please contact:

Isha Trivedi Glenmark, Mumbai, India Tel: +91 22 4018 9801 Email: corpcomm@glenmarkpharma.com

==> picture [561 x 28] intentionally omitted <==

2